-
Uncategorized2 months agoSTAT+: FDA pressures drugmakers to report trial results
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. My colleague recently...
-
Uncategorized2 months agoFrom Colossal to Chickens: The Scientists Behind Neion Bio’s Biologics Platform
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond...
-
Uncategorized2 months ago
Lilly investing billions to prepare for overseas oral GLP-1 launches
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity...
-
Uncategorized2 months ago
Lilly wants to bridge cancer care gap with $300M ADC biotech buy
Eli Lilly is putting its obesity windfall to work again, striking a new deal to acquire CrossBridge Bio, a small Texas biotech known for its cancer...
-
Uncategorized2 months agoSTAT+: Hospitals offer chatbots to fight off ChatGPT
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your...
-
Uncategorized2 months agoSTAT+: Pharmalittle: We’re reading about an FDA push for trial transparency, a Novo-OpenAI deal, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where...
-
Uncategorized2 months ago
Eli Lilly to pay up to $300M for cancer biotech CrossBridge Bio
Biotech entrepreneur Michael Torres is selling his antibody-drug conjugate startup CrossBridge Bio to Eli Lilly in a deal worth up to $300 million, the two companies...
-
Uncategorized2 months agoA fluoride shortage for some U.S. water systems
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. Tomorrow’s the deadline for filing taxes....
-
Uncategorized2 months ago
Parker Institute doubles down on cancer vaccines as part of ongoing reboot
At a moment when many drug developers are shying away from politically charged mRNA vaccines, one prominent research funder is doubling down on the technology’s promise...
-
Uncategorized2 months ago
Cell therapy biotech Obsidian leverages Galera reverse merger to go public
After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a partner via a reverse merger with Obsidian Therapeutics that...
